The Alzheimer’s Association International Conference (AAIC) is the largest international meeting dedicated to advancing dementia science. It convenes basic science and clinical researchers, next-generation investigators, clinicians, and the research community to share research discoveries toward preventing and treating Alzheimer disease.
August 07, 2022
The chief medical officer and cofounder of Linus Health provided insight on the outlook of acoustic measures and machine learning to further classify cognitive impairment. [WATCH TIME: 4 minutes]
August 06, 2022
Jagan A. Pillai, MD, PhD, neurologist, Cleveland Clinic Lou Ruvo Center for Brain Health, discussed a recent study which found faster clinical progression in those with nonamnestic initial cognitive symptoms.
August 05, 2022
Effect modification by cognitive status and APOE genotype revealed greater effects of mild behavioral impairment with apathy in those who had normal cognition or in non-APOE ɛ4 groups.
August 05, 2022
The nephrologist at Mayo Clinic provided insight on new data showing elevated extracellular vesicles of neurovascular origin in women with a history of severe preeclampsia years after pregnancy. [WATCH TIME: 4 minutes]
August 04, 2022
The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed new findings on whether initial cognitive symptoms have similar rates of functional decline across a handful of neurodegenerative disorders. [WATCH TIME: 3 minutes]
August 04, 2022
In addition to significant associations between executive memory and cognition, baseline neurofilament light levels and age trended toward significance.
August 03, 2022
The chief medical officer and cofounder of Linus Health provided background on the reasoning for the measures used in a new machine learning algorithm that classifies cognitive status. [WATCH TIME: 3 minutes]
August 03, 2022
During a Focused Topic Session at the 2022 Alzheimer’s Association International Conference, NeurologyLive® inquired with a panel of experts about the possibility of exploring a combination approach to Alzheimer disease as the future of treatment.
August 03, 2022
All severities of Alzheimer disease showed statistically significant benefits from the exercise program relative to controls, with more mild groups demonstrating the most improvement.
August 02, 2022
The monoclonal antibody that preferentially targets Aß oligomers failed to meet either of its coprimary end points—despite favorable results over the placebo group—in individuals who were unimpaired but at risk for AD.
FDA Extends Review of Omaveloxolone in Friedreich Ataxia
The Wide-Reaching Impact of Multiple Sclerosis DMT Wastes: Darin T. Okuda, MD; Karin Cook
Pepinemab’s Upregulation of SEMA4D Expression Warrants Further Development in Huntington, Alzheimer Disease
Future Relapse Remission in Multiple Sclerosis Impacted by Retinal Layer Thinning